MedTrace Logo

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

NCT07198191 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200000

Last updated 2025-09-30

No results posted yet for this study

Summary

This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Using the nationwide database from the Korean National Health Insurance Service, the investigators will compare cardiovascular outcomes between patients treated with SGLT2 inhibitors and those treated with dipeptidyl peptidase-4 (DPP4) inhibitors after AMI. The study period includes patients diagnosed with AMI between September 2014 and June 2021, with follow-up data available through June 2022. The primary outcomes include major cardiovascular events (death, myocardial infarction, stroke) and bleeding events. This study will provide real-world evidence on the effectiveness and safety of SGLT2 inhibitors in routine clinical practice following AMI among patients with T2DM in Korea.

Conditions

  • Acute Myocardial Infarction (AMI)
  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)

Exposure to SGLT2 inhibitors following AMI in patients with T2DM

DRUG

DPP4 inhibitors

Exposure to DPP4 inhibitors following AMI in patients with T2DM

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical Corp.

    collaborator INDUSTRY

  • Health Insurance Review & Assessment Service

    collaborator UNKNOWN

  • Yonsei University

    lead OTHER

Principal Investigators

  • Yongcheol Kim, MD, PhD · Yonsei University Health System, Yongin Severance Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-01
Primary Completion
2022-06-30
Completion
2026-08-30

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07198191 on ClinicalTrials.gov